Division of Molecular Regenerative Medicine, Course of Advanced Medicine, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Activation and proliferation of glomerular mesangial cells play an important role in the development of mesangioproliferative glomerulonephritis. We investigated the role of hepatocyte growth factor (HGF) in regulating activated mesangial cell proliferation. In glomeruli of normal rats, mesangial cells barely expressed the c-Met/HGF receptor. However, when mesangioproliferative glomerulonephritis was induced in rats by the administration of an anti-Thy 1.1 antibody, glomerular HGF expression transiently decreased along with mesangiolysis, and activation of mesangial cells was associated with upregulation of the c-Met receptor. Activated mesangial cells in culture also expressed the c-Met/HGF receptor. Although addition of HGF to cultured mesangial cells did not increase DNA synthesis, HGF did diminish PDGF-induced DNA synthesis. PDGF induced activation of ERK, which continued for at least 48 h. When PDGF and HGF were simultaneously added, HGF inhibited the prolonged activation of ERK, which suggests that early inactivation of PDGF-induced ERK may be involved in the inhibitory effect of HGF on mesangial cell proliferation. Furthermore, administration of HGF to rats with anti-Thy 1.1 nephritis resulted in a selective suppression of activated mesangial cell proliferation, and this suppressive effect was associated with attenuation of phosphorylated glomerular ERK. These results indicate that HGF counteracts PDGF-induced mesangial cell proliferation and functions as a negative regulator of activated mesangial cell proliferation.
hepatocyte growth factor; myofibroblast-like cell; c-met; ERK
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
GLOMERULAR MESANGIAL CELLS mechanically support glomerular capillary loops and control the rate of plasma ultrafiltration under physiological conditions. On the other hand, mesangial cell proliferation is a key feature of a variety of human glomerular diseases, including IgA nephropathy, lupus nephritis, variants of idiopathic focal sclerosis, and amyloid or diabetic nephropathy (12). In these diseases, mesangial cell proliferation is associated with a phenotypic change into myofibroblast-like cells (we here refer these to "activated" mesangial cells) (17). In experimental models of nephritis, mesangial cell proliferation frequently precedes and is linked to an increase in the extracellular matrix in the glomerulus (9). Although some proliferation and phenotypic changes in mesangial cells are likely to benefit the host in the physiologically reparative response to tissue injury, excessive proliferation of activated mesangial cells leads to the development of glomerulosclerosis. Therefore, a better understanding of regulatory mechanisms involved in mesangial cell proliferation would provide useful insights into therapeutic strategies to treat humans with progressive glomerular diseases.
Hepatocyte growth factor (HGF), originally identified and cloned as a mitogen for mature hepatocytes (31, 32), exhibits multiple biological activities in a wide variety of cells (22, 27, 38) through the c-Met receptor tyrosine kinase (6). Several lines of evidence indicate an important role for HGF in the morphogenesis of organs during development (3, 35). Physiologically, HGF has organotrophic functions in the regeneration and protection of various organs from injuries (22, 27). Biological activities of HGF are likely to support tissue organization during development and regeneration. In the kidney, biological and renotropic roles of HGF have been well noted. HGF has mitogenic, morphogenic (induction of branching tubulogenesis), and anti-cell death actions on renal tubular epithelial cells (3, 28). In the glomerulus, HGF induces a mitotic response in glomerular endothelial cells (37). Cyclosporine A-induced apoptosis in glomerular epithelial cells was prevented by HGF (1). In response to acute renal injury, the expression of HGF increases and HGF plays a role in renal regeneration and protection from injuries (3, 28). Furthermore, the renotropic role of HGF after renal injury led to therapeutic approaches for treatment of renal diseases, including acute and chronic renal diseases in experimental models (7, 20, 29). Past approaches shed light on biological and renotropic roles of HGF in renal epithelial and endothelial cells; however, the potential functions of HGF in regulating mesangial cell proliferation and behavior have been discussed in only a few studies (19, 21, 37).
In the present study, we investigated the role of HGF and the c-Met receptor in the proliferation of activated mesangial cells, using the most widely studied experimental model for mesangioproliferative glomerulonephritis, anti-Thy 1.1 glomerulonephritis (11). Our findings indicate that HGF is a negative regulator of activated mesangial cell proliferation.
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Animals and materials. Male Wistar rats (7-8 wk old; 190-210 g) were purchased from SLC Japan (Hamamatsu, Japan). All animal experiments were done in accordance with National Institute of Health guidelines, as dictated by the animal care facility at Osaka University Graduate School of Medicine. Recombinant human HGF was purified from cultured media of Chinese hamster ovary cells transfected with cDNA, which encodes a variant type of human HGF with five deleted amino acid residues in the first kringle domain (20, 29, 30). The purity of HGF exceeded 98%, as determined by SDS-PAGE plus protein staining. Recombinant human PDGF-BB was purchased from R&D Systems (Minneapolis, MN). B cell hybridoma (OX-7), which produces anti-rat Thy 1.1 mouse monoclonal IgG1, was a gift from the Cell Resource Center for Biomedical Research, Tohoku University. Hybridoma cells were administered intraperitoneally into male BALB/c mice (SLC Japan), and ascites was obtained from these mice.
Experimental mesangioproliferative glomerulonephritis. To induce anti-Thy 1.1 glomerulonephritis in rats, the ascites obtained from the mice was given intravenously to rats at 25 µl/rat. Rats were divided into two groups so that the average concentration of urinary protein collected over 34-46 h after anti-Thy 1.1 antibody treatment was equal in each group. HGF (600 µg/kg body wt in 0.5 ml saline) or an equal volume of saline alone was given subcutaneously twice a day from 48 h after anti-Thy 1.1 treatment. After administration of HGF, plasma human HGF levels increased to 12.3, 13.4, and 7.2 ng/ml at 1, 2, and 6 h, whereas human HGF levels in renal tissue were 11.2, 12.6, and 5.8 ng/g tissue at 1, 2, and 6 h, respectively (data not shown). 5-Bromo-2'-deoxyuridine (BrdU; Nacalai Tesque, Kyoto, Japan) was given intraperitoneally (100 mg/kg body wt) 2 h before the rats were killed.
Real-time quantitative RT-PCR.
For analysis of changes in glomerular gene expression in anti-Thy 1.1 glomerulonephritis, glomeruli were isolated from kidneys of nephritic
rats. In brief, renal cortexes of each rat were subjected to
differential sieving (25) at 4°C, then 200-300
glomeruli/rat were collected under microscopy and stored at 80°C
until use. Total RNA was extracted from purified glomeruli using an
RNeasy Mini kit and RNase-Free DNase Set (Qiagen), according to the
manufacturer's instructions. Ten microliters of total RNA solution
were subjected to reverse transcription into first-strand cDNA with a
random hexaprimer using Superscript II RT (Invitrogen, Carlsbad, CA). TaqMan quantitative PCR was done using the ABI PRISM 7700 Sequence Detector System (PerkinElmer Biosynthesis, Foster City, CA),
as described elsewhere (30). Sequences for primers and
TaqMan fluorogenic probes were as follows. For rat HGF, the
forward primer was 5'-AAG AGT GGC ATC AAG TGC CAG-3'; the reverse
primer was 5'-CTG GAT TGC TTG TGA AAC ACC-3'; and the probe was
5'(FAM)-TGA TCC CCC ATG AAC ACA GCT TTT TG -(TAMRA) 3'. For rat PDGF-B
chain, the forward primer was 5'-TCC AGA TCT CGC GGA ACC T-3'; the
reverse primer was 5'-CTG CAC ATT GCG GTT ATT GC-3'; and the probe was 5'(FAM)-CGA TCG CAC CAA TGC CAA CTT CC-(TAMRA) 3'. For GAPDH, the
forward primer was 5'-CCA TCA CTG CCA CTC AGA AGA C-3'; the reverse
primer was 5'-TCA TAC TTG GCA GGT TTC TCC A-3'; and the probe was
5'(FAM)-CGT GTT CCT ACC CCC AAT GTA TCC GT-(TAMRA) 3'. Experimental
samples were matched to a standard curve generated by amplifying
serially diluted products, using the same PCR protocol. To correct for
variability in RNA recovery and for efficiency of reverse
transcription, GAPDH cDNA was amplified and quantitated in each cDNA preparation.
Histological analysis.
Tissues were fixed in neutral buffered formalin (pH 7.4), embedded in
paraffin, and then sections were stained with hematoxylin and eosin.
Forty-eight glomerular cross sections from each rat were examined, and
the mean number of nuclei per glomerular cross section was measured.
For immunohistochemical staining, tissues were fixed in 70% ethanol
for detection of HGF. The primary antibodies used were polyclonal
anti-rat HGF (30). Tissue sections were subjected to the
avidin-biotin coupling technique, using a commercial kit (Vecstastain
Elite ABC, Vector Laboratories, Burlingame, CA), according to the
manufacturer's instructions. To identify activated mesangial cells,
peroxidase-conjugated monoclonal anti-human -smooth muscle actin
(
-SMA; DAKO, Glostrup, Denmark) was used. Glomerular staining for
-SMA was evaluated by the scoring method principally described by
Floege et al. (13). In each sample, 48 glomerular cross
sections were examined, and two individual observers made evaluations
of all the slides.
Cell culture and measurement of cell growth. Mesangial cells were prepared from 8-wk-old male Wistar rats by a differential sieving method and characterized as described (25). Cells were cultured in DMEM supplemented with 20% FCS, 0.5 µg/ml streptomycin, 100 U/ml penicillin G, and 0.25 µg/ml amphotericin B. For all experiments, we used cells of passages 4-10. For measurement of DNA synthesis, cells were seeded in 96-well culture plates (5 × 103 cells/well) and cultured for 24 h. Under these conditions, a cell confluence of ~95% was reached. Cells were serum-starved for 48 h in medium supplemented with 0.5% FCS, and then the medium was replaced with fresh medium and cells were further cultured for 48 h in the absence or presence of PDGF and/or HGF. The cells were pulse-labeled with [3H]thymidine (1.0 µCi/ml) for 5 h, and the amount of [3H]thymidine incorporated into nuclei was measured, as described elsewhere (32). Six wells were used for each condition.
Western blotting. To detect c-Met receptor expression in the cultured cells, the cells were seeded in 90-mm culture dish (2 × 105 cells/dish), cultured for 4 days, serum-starved for 24 h, then lysed in sample buffer for SDS-PAGE. The lysate was subjected to SDS-PAGE on a 6% polyacrylamide gel, and proteins were electroblotted on polyvinylidene difluoride membranes (Bio-Rad, Hercules, CA). After blocking, the membrane was sequentially incubated with the anti-mouse c-Met antibody and horseradish peroxidase-conjugated anti-rabbit IgG. Signals were visualized using an enhanced chemiluminescence reagent (Amersham Pharmacia Biotech).
For analysis of ERK phosphorylation in cultured mesangial cells, cells were seeded in six-well culture plates (3 × 104 cells/well) and cultured for 24 h. Cells were serum-starved for 48 h then treated with 20 ng/ml PDGF-BB and/or 30 ng/ml HGF for the indicated periods. Cells were washed once with ice-cold PBS, snap-frozen, thawed, and lysed with lysis buffer composed of (in mM) 20 mM Tris · HCl (pH 7.5), 150 NaCl, 10 EDTA, 2 Na3VO4, 10 NaF, and 1 PMSF as well as 1.0% Triton X-100, 0.1% SDS, and 10 µg/ml each of leupeptin, antipain, and pepstatin. The cell lysate was centrifuged at 12,000 g for 30 min. Protein concentration in the cell lysate was measured, using a DC protein assay kit (Bio-Rad). The extract (20 µg protein) was resolved by SDS-PAGE on a 12% polyacrylamide gel under reducing conditions and transferred onto polyvinylidene difluoride membrane. After blocking, the membrane was sequentially incubated with anti-phospho-p44/p42 MAPK (ERK1/2) monoclonal antibody (E10; New England BioLabs, Beverly, MA), biotinylated anti-mouse IgG (Vector Laboratories), and horseradish peroxidase-conjugated streptavidin (Amersham Pharmacia Biotech). To detect total ERK protein, the same membrane was stripped and reprobed with anti-ERK1 antibody (K-23; Santa Cruz Biotechnology) as the primary antibody. The band densities of immunoblots were analyzed using National Institutes of Health Image software (Wayne Rasband Analytics, NIH, http://rsb.info.nih.gov/nih-image/). For analysis of glomerular ERK phosphorylation, rats were perfused with ice-cold PBS containing (in mM) 10 EDTA, 2 Na3VO4, 50 NaF, and 2 PMSF as well as 10 µg/ml each of leupeptin, antipain, and pepstatin. Glomeruli were isolated using the differential sieving method and were immediately lysed with RIPA buffer composed of (in mM) 50 Tris · HCl (pH 7.5), 150 NaCl, 1 EDTA, 2 Na3VO4, 50 NaF, and 2 PMSF as well as 0.1% SDS, 1% Nonidet P-40, 0.1% sodium deoxycholate, and 10 µg/ml each of leupeptin, antipain, and pepstatin. The lysate was centrifuged at 12,000 g for 30 min, and the supernatant containing 100 µg of protein was subjected to SDS-PAGE, followed by immunoblot analysis, as described above.ELISA for glomerular PDGF-BB. For measurement of glomerular PDGF levels, glomeruli were isolated from the kidney 4 days after anti-Thy 1.1 treatment. Glomeruli were extracted in buffer composed of 20 mM Tris · HCl (pH 7.5), 2 M NaCl, 0.1% Tween 80, 1 mM EDTA, 1 mM PMSF, and 10 µg/ml each of leupeptin, antipain, and pepstatin. Glomerular PDGF levels were measured using a commercial kit (Quantikine human PDGF-BB, R&D systems), according to the manufacturer's instruction.
Statistical analysis. For statistical analysis, we used Student's unpaired t-test or ANOVA to determine the statistical significance. A P value <0.05 was considered to be statistically significant.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Change in glomerular HGF expression in anti-Thy 1.1 glomerulonephritis.
After administration of the anti-Thy 1.1 antibody, glomeruli showed
changes typical of mesangioproliferative glomerulonephritis, as
reported (11). A loss of mesangial cells associated with disruption of the mesangial matrix (mesangiolysis) was seen on days 1-2, and mesangial cell proliferation began from
day 2. Expression of -SMA, a marker of activated
mesangial cells, was undetectable in normal glomeruli but was
detectable from 2 days after anti-Thy 1.1 treatment (data not shown).
The overshooting mesangial cell growth was observed on days
4 and 8. To determine the potential involvement of HGF
in pathophysiological changes in anti-Thy 1.1 nephritis, we first
analyzed changes in glomerular expression of HGF during progression of
glomerulonephritis (Fig. 1). Glomerular HGF mRNA levels decreased on day 2 (~29% compared with
the value at day 0), the time when glomerular cell loss was
most prominent (Fig. 1A). The HGF mRNA level then increased
toward day 8 and returned to ~80% of the pretreatment
level. To determine the localization of HGF, immunohistochemical
examination was made on the glomeruli of anti-Thy 1.1 glomerulonephritis. In normal glomeruli, HGF was identified mainly in
the capillary luminal areas composed of endothelial cells, whereas weak
signals were sparse in mesangial areas (Fig. 1B, arrowhead
and inset, day 0). On day 2 after
anti-Thy 1.1 treatment, glomerular cells markedly decreased, and HGF
expression was noted also on remaining mesangial-like cells, which were
mutipolar and located between clusters of capillary loops (Fig.
1B, arrow, day 2). HGF expression became
predominant in mesangial areas rather than capillary areas, from 4 days
after anti-Thy 1.1 treatment. On day 8, HGF expression
became extensive, accompanied by glomerular hypercellularity, and this
was consistent with the recovery of HGF mRNA levels. At this time,
HGF-positive signals were mainly noted in mesangial areas (Fig.
1B, arrow and inset, day 8). These results suggest that the temporal decrease in HGF mRNA levels in this
model may be due to glomerular injuries of intrinsic cells (possibly
including endothelial and mesangial cells) caused by mesangiolytic
events. On the other hand, plasma HGF levels did not change
significantly during the progression of glomerulonephritis.
|
Induction of the c-Met receptor in activated mesangial cells.
Next, we analyzed expression of the c-Met/HGF receptor in glomeruli
(Fig. 2A). In the normal
glomerulus, c-Met receptor expression was evident in cells, presumably
epithelial and endothelial cells based on their localization and
morphology (Fig. 2A, center top). When
c-Met staining was merged with Thy 1.1 staining, a marker of mesangial
cells, c-Met-positive cells and Thy 1.1-positive cells were mostly
noncolocalized but not exclusively, thereby indicating that mesangial
cells in normal glomeruli are mostly c-Met negative (Fig.
2A, top). On the other hand, when
glomerular c-Met expression was analyzed in rats with anti-Thy
1.1 nephritis, based on double immunohistochemistry of c-Met and
-SMA (Fig. 2A, bottom center and
left),
-SMA-positive cells were mostly c-Met positive,
thus indicating that the
-SMA-positive activated mesangial cells
expressed the c-Met receptor (Fig. 2A, bottom right). These results indicate that the c-Met receptor is
inducible in mesangial cells during activation toward
myofibroblast-like cells, and hence HGF may play a role in regulating
activated mesangial cell behavior. On the other hand, when we measured
the change in c-Met mRNA expression in isolated glomeruli using
quantitative PCR, glomerular c-Met mRNA expression did not change
significantly.
|
Reduction of PDGF-induced DNA synthesis by HGF in cultured
mesangial cells.
Because induction of the c-Met receptor in activated mesangial cells
and regulation of HGF expression suggested the potential involvement of
HGF in the pathophysiology of mesangioproliferative glomerulonephritis, we next asked whether HGF would regulate the proliferation of activated mesangial cells in culture. Because PDGF is
the most potent known mitogen for mesangial cells (12) and
PDGF induced in glomeruli with anti-Thy 1.1 nephritis is involved in
the proliferation of mesangial cells (10, 16), mesangial cells were cultured in the absence or presence of HGF, PDGF, or their
combination and subjected to measurement of DNA synthesis (Fig.
3A). Consistent with reported
data (14), addition of PDGF stimulated DNA synthesis of
mesangial cells and the stimulatory effect of PDGF was maximal at
concentrations over 20 ng/ml (Fig. 3A and data not shown).
HGF alone up to 100 ng/ml had no significant effect on DNA synthesis of
mesangial cells. However, the simultaneous addition of HGF and PDGF
dose dependently inhibited PDGF-induced DNA synthesis, and 10-30
ng/ml HGF inhibited DNA synthesis to the basal level seen without PDGF.
|
|
Suppression of mesangial cell proliferation, glomerular ERK
phosphorylation, and -SMA expansion in anti-Thy 1.1 glomerulonephritis by HGF.
Based on the finding that HGF inhibited the proliferation of activated
mesangial cells stimulated by PDGF in vitro, we considered it important
to determine whether administration of HGF would exert negative
regulatory functions in the expansion of mesangial cells during
progression of anti-Thy 1.1 nephritis. For this purpose, recombinant
human HGF was repeatedly administrated later than 2 days after
injection of anti-Thy 1.1 antibody (Fig.
5A). Because disruption of
glomerular construction occurs during the first 2 days after anti-Thy
1.1 treatment (11), treatment with HGF later than 2 days
after anti-Thy 1.1 treatment excludes the possibility that HGF would
affect the onset of nephritis itself in this model. Compared with
control saline-treated rats, the mean number of total cells per
glomerulus significantly decreased on days 4 and 8 in HGF-treated rats (Fig. 5B). To observe
whether a decrease in the number of cells in glomeruli after HGF
treatment was due to a decrease in the number of proliferating cells,
cells undergoing DNA synthesis were determined based on BrdU
incorporation and subsequent immunohistochemistry (Fig.
6A). The number of
BrdU-positive cells per glomerulus in HGF-treated rats decreased to
74.7% on day 4 and 58.0% on day 8, compared
with findings in saline-treated rats. On the other hand, apoptotic
cell death in activated mesangial cells was proposed to be a cell
clearance mechanism in anti-Thy 1.1 nephritis, thereby contributing to
the resolution of glomerular hypercellularity (2).
However, during our present observation, the number of terminal
deoxynucleotidyl transferase-mediated dUTP-biotin nick-end
labeling-positive apoptotic cells was few, and there was not a
significant change with HGF treatment (data not shown).
|
|
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
In the kidney, activation of glomerular mesangial cells in response to glomerular damage and proliferation of these cells are thought to be risk factors for the progression of glomerular nephritis to irreversible glomerular scarring and play an important role in the pathogenesis of a variety of glomerular diseases (12). Therefore, understanding regulatory mechanisms governing proliferation of mesangial cells is important in designing effective treatments for glomerular nephritis and gaining a better understanding of pathophysiological aspects. In this study, we demonstrated for the first time that the c-Met receptor was induced in mesangial cells on stimulus toward activated mesangial cells and that HGF suppressed PDGF-induced proliferation of activated mesangial cells both in vivo and in vitro.
During successive cultivation, mesangial cells spontaneously undergo a
phenotypic change into activated, myofibroblast-like cells
(8). Previous reports showed that mesangial cells express the c-Met receptor in vitro, but the effects of HGF on cultured mesangial cells and in vivo expression of the c-Met receptor in mesangial cells were controversial (19, 21, 37). In the present study, we found that mesangial cells barely expressed the c-Met
receptor in the normal glomerulus, but after anti-Thy 1.1 treatment the
c-Met receptor was induced in -SMA-positive activated mesangial
cells. Thus in glomerular mesangial cells, expression of the c-Met
receptor is inducible, when mesangial cells are activated to become
-SMA-positive myofibroblast-like cells. Although mechanisms for
induction of the c-Met receptor during activation of mesangial cells
remain to be addressed, Liu et al. (24) reported that in
cultured mesangial cells the c-Met receptor was upregulated by several
growth factors, including PDGF. Therefore, the increased expression of
growth factors such as PDGF in this model (15) may be
partially responsible for c-Met receptor induction in this model.
Infusion of PDGF into the kidney or transfection of the PDGF gene in the kidney selectively induced mesangial cell proliferation (10, 16). Conversely, neutralization of PDGF resulted in the suppression of mesangial cell proliferation (18, 33). Similarly, it was reported that glomerular PDGF and PDGF receptor expression are increased in patients with various forms of glomerulonephritis (12). Thus considering the close involvement of PDGF in mesangioproliferative glomerulonephritis, we investigated a potential role for HGF, focusing on mesangial cell proliferation in combination with a PDGF stimulus. Other studies have shown that HGF alone had no apparent effect on rat, mouse, or human mesangial cell proliferation (21, 37), or that it is weakly mitogenic (19). In the present study, HGF alone had no apparent effect on cultured mesangial cells, but HGF did suppress the proliferation of activated mesangial cells promoted by PDGF. Because HGF did not alter PDGF expression in cultured mesangial cells, we studied the activation of ERK, an intracellular event closely associated with mesangial cell proliferation. Recent reports demonstrated that ERK is a mediator of the proliferative response in mesangioproliferative glomerulonephritis (4) and that inhibition of ERK in the proliferative phase of anti-Thy 1.1 nephritis prevented mesangial cell proliferation (5). Importantly, we found that ERK was differently regulated after stimulation of cells with PDGF, HGF, or both combined. The earlier inactivation of ERK by the simultaneous addition of PDGF and HGF seems to explain the suppressive effect of HGF on PDGF-dependent growth in activated mesangial cells. Our study clearly showed the counteractive interaction of two different growth factors and their receptors, either of which has the tyrosine kinase receptor.
Consistent with in vitro findings on the counteractive effects of HGF
on PDGF-induced proliferation of activated mesangial cells,
administration of HGF to rats with anti-Thy 1.1 nephritis suppressed
glomerular ERK phosphorylation and the proliferation of activated
mesangial cells, and these events were associated with a reduction in
glomerular expansion of -SMA expression. Because HGF did not
significantly change the glomerular expression of PDGF, the
intracellular counteraction of HGF against PDGF-dependent mesangial
cell proliferation seems to be a predominant mechanism by which HGF
suppressed expansion of activated mesangial cells in
mesangioproliferative glomerulonephritis. Because endogenous glomerular
HGF expression was decreased, rather than increased, after anti-Thy 1.1 treatment, decreased glomerular HGF expression might to some extent and
in part allow for the proliferation of activated mesangial cells.
Ostendorf et al. (33) showed that the transient inhibition of PDGF-B chain by a specific aptamer during the mesangioproliferative phase in the irreversible glomerulosclerosis model diminished proliferation of activated mesangial cells and that this resulted in almost complete prevention of the development of renal failure and glomerular as well as tubulointerstitial scarring. Their results provide a strong argument against concerns that inhibition of overshooting mesangial cell growth after injury might lead to the inhibition of healing and thus exacerbate glomerular damage. A reduction in early glomerular proliferation may be important for any sequent reduction of glomerular scarring and renal failure. Whether antiproliferative effects of HGF on activated mesangial cells are associated with the prevention of glomerulosclerosis remains to be addressed, using a model for glomerulosclerosis.
Previous approaches using distinct animal models of tissue fibrosis
provided evidence that HGF has antifibrogenic actions on tissue
fibrosis, including liver cirrhosis (26, 34), renal tubulointerstitial fibrosis (29), and lung fibrosis
(36). Based on the notions that the c-Met receptor is
preferentially expressed in epithelial cells and endothelial cells
under physiological conditions and that transforming growth factor-
(TGF-
) plays a role in tissue fibrosis, these studies addressed
mechanisms involved in antifibrotic actions of HGF, focusing on cell
division and antiapoptosis in epithelial cells, expression of
TGF-
, and proteases involved in the breakdown of ECM (23, 26,
29, 34, 36). However, little attention was directed to the
potential role of HGF to directly attenuate stromal cell expansion. Our original findings here are that HGF exerts antiproliferative actions, directly targeting stromal myofibroblast-like cells. Our observations provide a better understanding of the pathogenic mechanisms of as well
as therapeutic approaches to fibrotic disorders, from the aspect of
tissue remodeling regulated by growth factor networks.
![]() |
ACKNOWLEDGEMENTS |
---|
We are grateful to M. Ohara for comments and language assistance.
![]() |
FOOTNOTES |
---|
This study was supported by a grant-in-aid from the Ministry of Education, Science, Technology, Sports, and Culture of Japan.
Address for reprint requests and other correspondence: T. Nakamura, Div. of Molecular Regenerative Medicine, Course of Advanced Medicine, Osaka Univ. Graduate School of Medicine, 2-2-B7 Yamada-oka, Suita, Osaka 565-0871, Japan (E-mail: nakamura{at}onbich.med.osaka-u.ac.jp).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
First published February 20, 2003;10.1152/ajprenal.00326.2002
Received 9 September 2002; accepted in final form 16 February 2003.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Amaike, H,
Matsumoto K,
Oka T,
and
Nakamura T.
Preventive effect of hepatocyte growth factor on acute side effects of cyclosporin A in mice.
Cytokine
8:
387-394,
1996[ISI][Medline].
2.
Baker, AJ,
Mooney A,
Hughes J,
Lombardi D,
Johnson RJ,
and
Savill J.
Mesangial cell apoptosis: the major mechanism for resolution of glomerular hypercellularity in experimental mesangial proliferative nephritis.
J Clin Invest
94:
2105-2116,
1994[ISI][Medline].
3.
Balkovetz, DF,
and
Lipschutz JH.
Hepatocyte growth factor and the kidney: it is not just for the liver.
Int Rev Cytol
186:
225-260,
1999[ISI][Medline].
4.
Bokemeyer, D,
Ostendorf T,
Kunter U,
Lindemann M,
Kramer HJ,
and
Floege J.
Differential activation of mitogen-activated protein kinases in experimental mesangioproliferative glomerulonephritis.
J Am Soc Nephrol
11:
232-240,
2000
5.
Bokemeyer, D,
Panek D,
Kramer HJ,
Lindemann M,
Kitahara M,
Boor P,
Kerjaschki D,
Trzaskos JM,
Floege J,
and
Ostendorf T.
In vivo identification of the mitogen-activated protein kinase cascade as a central pathogenic pathway in experimental mesangioproliferative glomerulonephritis.
J Am Soc Nephrol
13:
1473-1480,
2002
6.
Bottaro, DP,
Rubin JS,
Faletto DL,
Chan AM,
Kmiecik TE,
Vande Woude GF,
and
Aaronson SA.
Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product.
Science
251:
802-804,
1991[ISI][Medline].
7.
Dai, C,
Yang J,
and
Liu Y.
Single injection of naked plasmid encoding hepatocyte growth factor prevents cell death and ameliorates acute renal failure in mice.
J Am Soc Nephrol
13:
411-422,
2002
8.
Elger, M,
Drenckhahn D,
Nobiling R,
Mundel P,
and
Kriz W.
Cultured rat mesangial cells contain smooth muscle -actin not found in vivo.
Am J Pathol
142:
497-509,
1993[Abstract].
9.
Floege, J,
Alpers CE,
Burns MW,
Pritzl P,
Gordon K,
Couser WG,
and
Johnson RJ.
Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model.
Kidney Int
41:
297-309,
1992[ISI][Medline].
10.
Floege, J,
Eng E,
Young BA,
Alpers CE,
Barrett TB,
Bowen-Pope DF,
and
Johnson RJ.
Infusion of PDGF or basic FGF induces selective glomerular mesangial cell proliferation and matrix accumulation in rats.
J Clin Invest
92:
2952-2962,
1993[ISI][Medline].
11.
Floege, J,
Eng E,
Young BA,
and
Johnson RJ.
Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo.
Kidney Int Suppl
39:
S47-S54,
1993[Medline].
12.
Floege, J,
and
Johnson RJ.
Multiple roles for platelet-derived growth factor in renal disease.
Miner Electrolyte Metab
21:
271-282,
1995[ISI][Medline].
13.
Floege, J,
Johnson RJ,
Gordon K,
Iida H,
Pritzl P,
Yoshimura A,
Campbell C,
and
Alpers CE.
Increased synthesis of extracellular matrix in mesangial proliferative nephritis.
Kidney Int
40:
477-488,
1991[ISI][Medline].
14.
Floege, J,
Topley N,
Hoppe J,
Barrett TB,
and
Resch K.
Mitogenic effect of platelet-derived growth factor in human glomerular mesangial cells: modulation and/or suppression by inflammatory cytokines.
Clin Exp Immunol
86:
334-341,
1991[ISI][Medline].
15.
Iida, H,
Seifert R,
Alpers CE,
Gronwald RG,
Phillips PE,
Pritzl P,
Gordon K,
Gown AM,
Ross R,
Bowen-Pope DF,
and
Johnson RJ.
Platelet-derived growth factor (PDGF) and PDGF receptor are induced in mesangial proliferative nephritis in the rat.
Proc Natl Acad Sci USA
88:
6560-6564,
1991[Abstract].
16.
Isaka, Y,
Fujiwara Y,
Ueda N,
Kaneda Y,
Kamada T,
and
Imai E.
Glomerulosclerosis induced by in vivo transfection of TGF- or PDGF gene into the rat kidney.
J Clin Invest
92:
2597-2601,
1993[ISI][Medline].
17.
Johnson, RJ,
Iida H,
Alpers CE,
Majesky MW,
Schwartz SM,
Pritzl P,
Gordon K,
and
Gown AM.
Expression of smooth muscle cell phenotype by rat mesangial cells in immune complex nephritis.
J Clin Invest
87:
847-858,
1991[ISI][Medline].
18.
Johnson, RJ,
Raines EW,
Floege J,
Yoshimura A,
Pritzl P,
Alpers C,
and
Ross R.
Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet-derived growth factor.
J Exp Med
175:
1413-1416,
1992[Abstract].
19.
Kallincos, NC,
Pollard AN,
and
Couper JJ.
Evidence for a functional hepatocyte growth factor receptor in human mesangial cells.
Regul Pept
74:
137-142,
1998[ISI][Medline].
20.
Kawaida, K,
Matsumoto K,
Shimazu H,
and
Nakamura T.
HGF prevents acute renal failure and accelerates renal regeneration in mice.
Proc Natl Acad Sci USA
91:
4357-4361,
1994[Abstract].
21.
Kolatsi-Joannou, M,
Woolf AS,
Hardman P,
White SJ,
Gordge M,
and
Henderson RM.
The hepatocyte growth factor/scatter factor (HGF/SF) receptor, met transduces a morphogenetic signal in renal glomerular fibromuscular mesangial cells.
J Cell Sci
108:
3703-3714,
1995
22.
Kopp, JB.
Hepatocyte growth factor: mesenchymal signal for epithelial homeostasis.
Kidney Int
54:
1392-1393,
1998[ISI][Medline].
23.
Liu, Y,
Rajur K,
Tolbert E,
and
Dworkin LD.
Endogenous hepatocyte growth factor ameliorates chronic renal injury by activating matrix degradation pathways.
Kidney Int
58:
2028-2043,
2000[ISI][Medline].
24.
Liu, Y,
Tolbert EM,
Sun AM,
and
Dworkin LD.
Primary structure of rat HGF receptor and induced expression in glomerular mesangial cells.
Am J Physiol Renal Fluid Electrolyte Physiol
271:
F679-F688,
1996
25.
Matousovic, K,
Grande JP,
Chini CC,
Chini EN,
and
Dousa TP.
Inhibitors of cyclic nucleotide phosphodiesterase isozymes type-III and type-IV suppress mitogenesis of rat mesangial cells.
J Clin Invest
96:
401-410,
1995[ISI][Medline].
26.
Matsuda, Y,
Matsumoto K,
Ichida T,
and
Nakamura T.
Hepatocyte growth factor suppresses the onset of liver cirrhosis and abrogates lethal hepatic dysfunction in rats.
J Biochem (Tokyo)
118:
643-649,
1995[Abstract].
27.
Matsumoto, K,
and
Nakamura T.
Emerging multipotent aspects of hepatocyte growth factor.
J Biochem
119:
591-600,
1996[Abstract].
28.
Matsumoto, K,
and
Nakamura T.
Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases.
Kidney Int
59:
2023-2038,
2001[ISI][Medline].
29.
Mizuno, S,
Kurosawa T,
Matsumoto K,
Mizuno-Horikawa Y,
Okamoto M,
and
Nakamura T.
Hepatocyte growth factor prevents renal fibrosis and dysfunction in a mouse model of chronic renal disease.
J Clin Invest
101:
1827-1834,
1998
30.
Nakamura, T,
Mizuno S,
Matsumoto K,
Sawa Y,
Matsuda H,
and
Nakamura T.
Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF.
J Clin Invest
106:
1511-1519,
2000
31.
Nakamura, T,
Nawa K,
and
Ichihara A.
Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats.
Biochem Biophys Res Commun
122:
1450-1459,
1984[ISI][Medline].
32.
Nakamura, T,
Nishizawa T,
Hagiya M,
Seki T,
Shimonishi M,
Sugimura A,
Tashiro K,
and
Shimizu S.
Molecular cloning and expression of human hepatocyte growth factor.
Nature
342:
440-443,
1989[ISI][Medline].
33.
Ostendorf, T,
Kunter U,
Grone HJ,
Bahlmann F,
Kawachi H,
Shimizu F,
Koch KM,
Janjic N,
and
Floege J.
Specific antagonism of PDGF prevents renal scarring in experimental glomerulonephritis.
J Am Soc Nephrol
12:
909-918,
2001
34.
Ueki, T,
Kaneda Y,
Tsutsui H,
Nakanishi K,
Sawa Y,
Morishita R,
Matsumoto K,
Nakamura T,
Takahashi H,
Okamoto E,
and
Fujimoto J.
Hepatocyte growth factor gene therapy of liver cirrhosis in rats.
Nat Med
5:
226-230,
1999[ISI][Medline].
35.
Woolf, AS,
Kolatsi-Joannou M,
Hardman P,
Andermarcher E,
Moorby C,
Fine LG,
Jat PS,
Noble MD,
and
Gherardi E.
Roles of hepatocyte growth factor/scatter factor and the met receptor in the early development of the metanephros.
J Cell Biol
128:
171-184,
1995[Abstract].
36.
Yaekashiwa, M,
Nakayama S,
Ohnuma K,
Sakai T,
Abe T,
Satoh K,
Matsumoto K,
Nakamura T,
Takahashi T,
and
Nukiwa T.
Simultaneous or delayed administration of hepatocyte growth factor equally represses the fibrotic changes in murine lung injury induced by bleomycin.
Am J Respir Crit Care Med
156:
1937-1944,
1997
37.
Yo, Y,
Morishita R,
Yamamoto K,
Tomita N,
Kida I,
Hayashi S,
Moriguchi A,
Kato S,
Matsumoto K,
Nakamura T,
Higaki J,
and
Ogihara T.
Actions of hepatocyte growth factor as a local modulator in the kidney: potential role in pathogenesis of renal disease.
Kidney Int
53:
50-58,
1998[ISI][Medline].
38.
Zarnegar, R,
and
Michalopoulos GK.
The many faces of hepatocyte growth factor; from hepatopoiesis to hematopoiesis.
J Cell Biol
129:
1177-1180,
1995[ISI][Medline].